Markets:

Overview

News

Currencies

International

Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

33.99 -0.32 (-0.93%)

Streaming Delayed Price Updated: 11:59 AM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse

February 10, 2026

February 10, 2026 Introduction As of February 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a pivotal juncture. Five years after its high-profile inception, the company has shed its skin as a...

Via Finterra

Topics Economy World Trade

Teva (TEVA) Q4 2024 Earnings Call Transcript ↗

February 05, 2026

Teva (TEVA) Q4 2024 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Teva (TEVA) Q3 2024 Earnings Call Transcript ↗

February 05, 2026

Teva (TEVA) Q3 2024 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) Shows Perfect Technical Setup for Breakout ↗

January 28, 2026

Via Chartmill

Why Is TEVA Stock Rising Pre-Market Today? ↗

January 12, 2026

Via Stocktwits

Harel Insurance Sold $330 Million of Invesco KBW Bank ETF ↗

February 05, 2026

Invesco KBW Bank ETF tracks a benchmark of major U.S. banking institutions, offering targeted sector exposure and a moderate yield.

Via The Motley Fool

Topics ETFs Regulatory Compliance

Aytu BioPharma AYTU Q2 2026 Earnings Transcript ↗

February 03, 2026

Aytu BioPharma AYTU Q2 2026 Earnings Transcript

Via The Motley Fool

Bank ETF Up 20% in a Year, but This Fund Just Cut a $10 Million Position ↗

January 29, 2026

The Invesco KBW Bank ETF tracks a sector-specific index of leading U.S. banking firms, emphasizing large and regional institutions.

Via The Motley Fool

Topics ETFs Regulatory Compliance

Teva (TEVA) Q3 2025 Earnings Call Transcript ↗

January 28, 2026

Teva (TEVA) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth and the High-Stakes Pivot to Oncology

January 28, 2026

As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused...

Via Finterra

Topics Economy Intellectual Property

The $100 Billion Milestone: Johnson & Johnson Pivots from 'Steady' 2025 to Growth-Focused 2026

January 27, 2026

NEW BRUNSWICK, N.J. — Johnson & Johnson (NYSE: JNJ) has officially closed the chapter on a year many analysts described as "transitional," reporting full-year 2025 earnings that met expectations while...

Via MarketMinute

Topics Earnings Economy Government

The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion

January 20, 2026

As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results....

Via MarketMinute

Topics Bankruptcy Earnings Economy

Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation

January 14, 2026

Date: January 14, 2026 Viatris Inc. (NASDAQ: VTRS) stands at a critical crossroads in early 2026. After years of functioning as a complex, debt-laden conglomerate formed from the massive merger of...

Via Finterra

Topics Earnings Economy Intellectual Property

Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story ↗

December 27, 2025

Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story

Via The Motley Fool

Topics Regulatory Compliance

Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 ↗

December 24, 2025

Duquesne Family Office's billionaire boss has jettisoned the faces of the artificial intelligence (AI) revolution in favor of a drugmaker whose shares have rallied 191% since the beginning of 2024.

Via The Motley Fool

Topics Artificial Intelligence

My Top 10 Portfolio Holdings for 2026 ↗

December 19, 2025

This combination of growth and value stocks has the tools and intangibles necessary to outperform in the year to come.

Via The Motley Fool

Topics Stocks

3 Things You Need to Know if You Buy Teva Pharmaceutical Stock Today ↗

December 17, 2025

Teva Pharmaceutical is more complex than you may realize, even though that's part of the company's plan.

Via The Motley Fool

Topics Intellectual Property

Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? ↗

December 14, 2025

Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.

Via The Motley Fool

Topics Intellectual Property

Glenview Capital Management Sells $71 Million of Alight Stake After Stock's 71% Drop ↗

December 09, 2025

Glenview Capital Management reduced its stake in Alight by roughly 16% during the third quarter.

Via The Motley Fool

Topics Regulatory Compliance

Glenview Doubles Down on Teva Stock With $72 Million Buy, According to Recent SEC Filing ↗

December 09, 2025

Glenview Capital Management added to its massive position in Teva Pharmaceuticals stock.

Via The Motley Fool

Topics Regulatory Compliance

Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035

December 03, 2025

The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge,...

Via MarketMinute

Topics Artificial Intelligence Death Intellectual Property

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks ↗

November 30, 2025

Stanley Druckenmiller is considered one of the greatest investors of all time.

Via The Motley Fool

Topics Artificial Intelligence

Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared ↗

November 27, 2025

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

Via Stocktwits

Topics ETFs

JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets ↗

November 26, 2025

JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season.

Via Stocktwits

Topics Economy Government

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗

November 26, 2025

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.

Via Investor's Business Daily

Topics Economy Government

Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report ↗

November 19, 2025

Jury convicts Done Global founder Ruthia He and former top doctor David Brody in a federal case alleging illegal Adderall distribution through the telehealth platform.

Via Benzinga

Topics Law Enforcement

Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗

November 14, 2025

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 11, 2025

Via Benzinga

Billionaire Stanley Druckenmiller Sold His Fund's Entire Stakes in Nvidia and Palantir for a Scorching-Hot Drug Stock That's Up 218% Since Mid-2023 ↗

November 11, 2025

Duquesne Family Office's billionaire boss has gone full contrarian by selling Wall Street's two artificial intelligence (AI) darlings and piling into a previously struggling pharmaceutical stock.

Via The Motley Fool

Topics Artificial Intelligence

Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today ↗

November 10, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

Headline News about Teva Pharmaceutical Industries Limited American Depositary Shares

Starting at $3.75/week.

Subscribe Today